Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human microbiome market.
Restraints:
# Lack of Expertise and Detailed Research
# Barriers in Proving the Causal Link Between Dysbiosis and Disease
Opportunities:
# Investigational New Drug (IND) Requirements for Fecal Microbiota
# Increasing Collaborations Create Growth Opportunities
Challenge:
# Government Regulations
Burning Issues:
# Abundant Opportunities in the Human Microbiome Field and Tremendous Research Investments
# Development of Human Microbiome Therapeutic Products
Get More Details | Download the PDF Brochure@ http://bit.ly/2QBkCgK
In this report, the human microbiome market is broadly segmented into product, application, disease, and region while, the human microbiome research spending market is broadly segmented into product and technology.
Microbiome-based drugs are expected to see an increased demand in the future, because of the rise in the incidence of lifestyle diseases and associated side-effects of various therapies across the world. Significant growth in the human microbiome market will be mainly driven by the rise in awareness of its use in diseases such as diarrhea, diabetes, obesity, and autoimmune disorders.
The need for early disease detection and diagnosis will also drive the use of microbiomes in molecular diagnostics. In addition, the representation of human microbiomes as validated targets for developing drugs and chemical entities will further boost growth in the market.
Advances in human microbiome-based diagnostic applications may offer a wide range of new technologies that will help in cost- and time-efficient disease diagnosis. With the introduction of microbiome techniques, the market will witness higher growth in the forecast period.
The growing awareness on healthcare has fueled the demand for products such as probiotics, prebiotics, medical foods, which is driving the growth of the human microbiome market segment. The largest product segment in this market is probiotics, which is expected to grow at a quick pace in the coming years. Market players have heightened their focus on this segment, as a result of which products launches in this sector have increased.
Read the Detailed Article@
Europe is expected to be the largest contributor to the human microbiome market, owing to the rise in the lifestyle diseases and increased demand and awareness of prebiotics and probiotics. On the other hand North America has the fastest growth rate. This is due to, the probiotics market in this region which is expected to grow rapidly due to the general affinity of the U.S. population towards probiotic dietary supplements and the concept of preventive healthcare.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and Company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and Company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
No comments:
Post a Comment